Radiothérapie stéréotaxique (RTST) pulmonaire des tumeurs de moins de 3 cm (stade I) et 5 cm (stade II) non opérées : 10 ans d’expérience de l’Institut du Cancer de Montpellier (ICM)

Gautier Defossez, 2018 Andler, 2018, Smoking and vaping in France, Rev Mal Respir, 35, 673, 10.1016/j.rmr.2018.01.008 Couraud, 2019, 1 2020 Qiao, 2003, The role of radiotherapy in treatment of stage I non-small cell lung cancer, Lung Cancer, 41, 1, 10.1016/S0169-5002(03)00152-1 Wisnivesky, 2005, Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer, Chest, 128, 1461, 10.1378/chest.128.3.1461 Nanda, 2015, Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis, Cancer, 121, 4222, 10.1002/cncr.29640 Ball, 2019, Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial, Lancet Oncol, 20, 494, 10.1016/S1470-2045(18)30896-9 Grills, 2010, Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer, J Clin Oncol, 28, 928, 10.1200/JCO.2009.25.0928 Lagerwaard, 2012, Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage i non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 83, 348, 10.1016/j.ijrobp.2011.06.2003 Palma, 2011, Treatment of stage i NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery, Radiother Oncol, 101, 240, 10.1016/j.radonc.2011.06.029 Scotti, 2019, Stereotactic ablative radiotherapy as an alternative to lobectomy in patients with medically operable stage I NSCLC: a retrospective, multicenter analysis, Clin Lung Can, 20, e53, 10.1016/j.cllc.2018.09.003 Zheng, 2014, Survival outcome after stereotactic body radiation therapy and surgery for stage i non-small cell lung cancer: a meta-analysis, Int J Radiat Oncol, 90, 603, 10.1016/j.ijrobp.2014.05.055 Chen, 2018, Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies, Int J Radiat Oncol Biol Phys, 101, 186, 10.1016/j.ijrobp.2018.01.064 Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Artic Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Franks, 2018, SABRTOOTH: a fasibility study of SABR versus surgery in patients with peripheral stage I NSCLC considered to be at higher risk for surgery, J Thorac Oncol, 13, S837, 10.1016/j.jtho.2018.08.1491 Fowler, 2010, 21 years of biologically effective dose, Br J Radiol, 83, 554, 10.1259/bjr/31372149 Onishi, 2004, Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study, Cancer, 101, 1623, 10.1002/cncr.20539 Videtic, 2017, Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline, Pract Radiat Oncol, 7, 295, 10.1016/j.prro.2017.04.014 Guckenberger, 2017, ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer, Radiother Oncol, 124, 11, 10.1016/j.radonc.2017.05.012 Wilke, 2019, ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery, Strahlenther Onkol, 195, 193, 10.1007/s00066-018-1416-x Chi, 2010, Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer, Clinical implications, 94, 1 Chen, 2018, Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies, Int J Radiat Oncol, 101, 186, 10.1016/j.ijrobp.2018.01.064 Khakwani, 2019, Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England, Thorax, 75, 237, 10.1136/thoraxjnl-2018-212493 Doi, 2019, Stereotactic body radiotherapy in patients with chronic obstructive pulmonary disease and interstitial pneumonia: a review, Int J Clin Oncol, 24, 899, 10.1007/s10147-019-01432-y Luo, 2019, Should stereotactic body radiotherapy doses be adjusted according to tumor size in early-stage non-small-cell lung cancer?. A systematic review and meta-analysis, Future Oncol, 15, 3071, 10.2217/fon-2019-0240 Parker, 2019, Impact of Tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors, Pract Radiat Oncol, 9, e90, 10.1016/j.prro.2018.09.003 Dunlap, 2010, Size matters: a comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT), J Thorac Cardiovasc Surg, 140, 583, 10.1016/j.jtcvs.2010.01.046 Ball, 2019, Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial, Lancet Oncol, 20, 494, 10.1016/S1470-2045(18)30896-9 Schneider, 2017, Stereotactic body radiotherapy for early-stage non–small-cell lung cancer: american society of clinical oncology endorsement of the american society for radiation oncology evidence-based guideline, J Clin Oncol, 36, 710, 10.1200/JCO.2017.74.9671 Feng, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Artic Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Onishi, 2011, Stereotactic body radiotherapy (SBRT) for operable Stage i non-small-cell lung cancer: Can SBRT be comparable to surgery?, Int J Radiat Oncol Biol Phys, 81, 1352, 10.1016/j.ijrobp.2009.07.1751 Eba, 2016, Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma: Comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A), Jpn J Clin Oncol, 46, 1, 10.1093/jjco/hyw058 Miyazaki, 2017, Surgery or stereotactic body radiotherapy for elderly stage I lung cancer?. A propensity score matching analysis, Surg Today, 47, 1476, 10.1007/s00595-017-1536-4 Ryckman, 2020, Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy, Radiat Oncol, 15, 33, 10.1186/s13014-020-1479-6 Thompson, 2018, The evolving toxicity profile of SBRT for lung cancer, Transl Lung Cancer Res, 8, 48, 10.21037/tlcr.2018.10.06 Dang, 2017, Efficacy of flattening-filter-free beam in stereotactic body radiation therapy planning and treatment: a systematic review with meta-analysis, J Med Imaging Radiat Oncol, 61, 379, 10.1111/1754-9485.12583 Palussière, 2018, Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial, J Cardiothorac Surg, 13, 91, 10.1186/s13019-018-0773-y Simon, 2007, Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients, Radiology, 243, 268, 10.1148/radiol.2431060088 Lanuti, 2009, Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer, J Thorac Cardiovasc Surg, 137, 160, 10.1016/j.jtcvs.2008.08.034 Hiraki, 2007, Percutaneous radiofrequency ablation for clinical stage I non-small cell lung cancer: results in 20 nonsurgical candidates, J Thorac Cardiovasc Surg, 134, 1306, 10.1016/j.jtcvs.2007.07.013 Pennathur, 2007, Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients, J Thorac Cardiovasc Surg, 134, 857, 10.1016/j.jtcvs.2007.04.060 Ambrogi, 2011, Long-term results of radiofrequency ablation treatment of stage i non-small cell lung cancer: A prospective intention-to-treat study, J Thorac Oncol, 6, 2044, 10.1097/JTO.0b013e31822d538d Fernando, 2005, Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates, J Thorac Cardiovasc Surg, 129, 639, 10.1016/j.jtcvs.2004.10.019 Yang, 2014, Percutaneous microwave ablation of stage i medically inoperable non-small cell lung cancer: Clinical evaluation of 47 cases, J Surg Oncol, 110, 758, 10.1002/jso.23701 Moore, 2015, Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients, J Vasc Interv Radiol, 26, 312, 10.1016/j.jvir.2014.12.006 Zemlyak, 2010, Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer, J Am Coll Surg, 211, 68, 10.1016/j.jamcollsurg.2010.03.020 Demaria, 2015, Role of local radiation therapy in cancer immunotherapy, JAMA Oncol, 1, 1325, 10.1001/jamaoncol.2015.2756 Formenti, 2013, Combining radiotherapy and cancer immunotherapy: a paradigm shift, JNCI J Natl Cancer Inst, 105, 256, 10.1093/jnci/djs629 Formenti, 2012, Radiation therapy to convert the tumor into an in situ vaccine, Int J Radiat Oncol, 84, 879, 10.1016/j.ijrobp.2012.06.020 Tian, 2020, Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis, Int J Radiat Oncol, 36, 1 Antonia, 2017, Durvalumab after chemoradiotherapy in stage iii non–small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Park, 2019, Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR, Radiat Oncol, 14, 105, 10.1186/s13014-019-1314-0 Finazzi, 2020, Clinical outcomes of stereotactic mr-guided adaptive radiation therapy for high-risk lung tumors, Int J Radiat Oncol, 107, 270, 10.1016/j.ijrobp.2020.02.025